Charles Schwab
ELTX icon

Charles Schwab’s Elicio Therapeutics ELTX Stock Holding History

Charles Schwab’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,575
Closed -$97K – 3566
2022
Q1 		$97K Hold
4,575
– – ﹤0.01% 3418
2021
Q4 		$133K Hold
4,575
– – ﹤0.01% 3412
2021
Q3 		$448K Buy
4,575
+1,254
+38% +$135K ﹤0.01% 3177
2021
Q2 		$433K Sell
3,321
-161
-5% -$23.2K ﹤0.01% 3197
2021
Q1 		$630K Buy
+3,482
New +$672K ﹤0.01% 3009

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Charles Schwab's ELTX Position: Q2 2022 in Review

Charles Schwab sold out of Elicio Therapeutics (ELTX) in Q2 2022, closing a stake of 4,575 shares — an estimated $97K sold.

Charles Schwab first reported a position in ELTX in Q1 2021 and held it in 5 quarters. The position peaked at $630K in Q1 2021. 43 funds tracked by Wall St. Rank hold ELTX as of Q2 2022.

  • Charles Schwab reported no remaining Elicio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Charles Schwab sold 4,575 Elicio Therapeutics shares in Q2 2022, an estimated $97K.
  • Charles Schwab first reported a position in Elicio Therapeutics in Q1 2021 and held it in 5 quarters.
  • Charles Schwab's Elicio Therapeutics position peaked at $630K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.